Wealth Enhancement Advisory Services LLC Decreases Position in Kenvue Inc. $KVUE

by · The Cerbat Gem

Wealth Enhancement Advisory Services LLC decreased its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 14.0% during the 3rd quarter, Holdings Channel reports. The firm owned 477,823 shares of the company’s stock after selling 77,491 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Kenvue were worth $7,750,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in Kenvue in the 2nd quarter valued at about $537,418,000. Independent Franchise Partners LLP grew its position in shares of Kenvue by 233.4% in the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. American Century Companies Inc. grew its position in shares of Kenvue by 38.6% in the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after purchasing an additional 8,436,166 shares during the last quarter. Amundi increased its stake in shares of Kenvue by 82.5% during the 2nd quarter. Amundi now owns 14,509,890 shares of the company’s stock worth $305,446,000 after purchasing an additional 6,559,261 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Kenvue by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after purchasing an additional 4,101,880 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $17.82 on Friday. The stock has a fifty day moving average price of $17.05 and a 200 day moving average price of $18.15. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The firm has a market capitalization of $34.14 billion, a P/E ratio of 23.76 and a beta of 0.60. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Insider Buying and Selling at Kenvue

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the stock in a transaction dated Friday, December 12th. The stock was bought at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the purchase, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.68% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Edward Jones cut Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. UBS Group decreased their price objective on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Jefferies Financial Group cut their target price on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. The Goldman Sachs Group reduced their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $15.00 price target (down from $26.00) on shares of Kenvue in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $20.23.

Check Out Our Latest Stock Report on Kenvue

Kenvue Company Profile

(Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Featured Stories

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).